TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20390807
Drug: Combined parent-child/family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined parent-child/family therapy treatment
Study: 20390807
Drug: Cognitive-behavioral individual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral individual child treatments
Study: 20390807
Drug: Individual child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual child treatments
Study: 17712672
Drug: Intratympanic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic treatment with AM‐111 at a concentration of 0.4 mg/ml or 2 mg/ml
Study: 10454450
Drug: DHA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (4 g/d)
Study: 9665096
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (4 g/d, control)
Study: 818720
Drug: Sotalol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (320 mg per day, 160 mg twice daily)
Study: 23368820
Drug: Ulinastatin (150,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (150,000 U by i.v. drip infusion for 2 hours)
Study: 19465485
Drug: High-dose octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose octreotide (60 mg/28 days)
Study: 8142675
Drug: Norfloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (200 mg orally, 2 or 4 times daily) + Amphotericin B (200 mg orally, 4 times daily)
Study: 2878598
Drug: Once-daily bevantolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily bevantolol (200 mg)
Study: 20135139
Drug: Bevacizumab administered
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab administered 20 days before vitrectomy
Study: 15811091
Drug: 8-MOP 0.01%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-MOP 0.01% gel plus UVA
Study: 11916547
Drug: Toxicity profile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toxicity profile of the treatment
Study: 10216807
Drug: Eprosartan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (200 mg b.i.d. to 300 mg b.i.d.)
Study: 10216807
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg o.d. to 20 mg o.d.)
Study: 10216806
Drug: Eprosartan +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan + Hydrochlorothiazide (HCTZ) (12.5‐25 mg o.d.)
Study: 7602359
Drug: Standard treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment: craniospinal radiotherapy (RT) followed by eight cycles of 1‐(2‐chloro‐ethyl)‐3‐cyclohexylnitrosourea (CCNU), vincristine (VCR), and prednisone
Study: 7602359
Drug: 8-in-1 chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-in-1 chemotherapy followed by RT and then eight additional cycles of 8-in-1
Study: 2228353
Drug: 13C-glucose (G)
Normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13C-glucose (G) ingestion
Study: 26177812
Drug: Delayed Treatment
Normalized name: GRANULES, DELAYED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Treatment (control group)
Study: 23636185
Drug: Anesthetic injection
Normalized name: Gelato Anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic injection alone (2 mL 1% lignocaine)
Study: 21289020
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone (0.4 mg/0.1 ml)
Study: 15918296
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (SIT) with high dose of allergenic extract (Group 2)
Study: 15918296
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (SIT) with low dose of allergenic extract (Group 1)
Study: 11783172
Drug: Xialian Yiyou
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xialian Yiyou Capsule (XLYYC)
Study: 11783172
Drug: Lizhu Dele
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lizhu Dele Capsule (Control)
Study: 1756252
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human factor VIII (BAY w 6240) administered prophylactically three times a week for 4 weeks
Study: 1756252
Drug: Plasma-derived factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived factor VIII preparation (pdFVIII)
Study: 6806184
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid solution containing 45% branched-chain amino acids (BCAAs)
Study: 6806184
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid solution with 10% branched-chain amino acids (BCAAs)
Study: 31082943
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) to the prostate
Study: 25902324
Drug: Manual control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual control (propofol infusion titrated manually)
Study: 24399452
Drug: Afatinib 20
Normalized name: afatinib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 20 mg with ritonavir
Study: 24399452
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg with ritonavir (simultaneous administration)
Study: 18853093
Drug: Candesartan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (8 mg od)
Study: 17176505
Drug: twice-daily rTMS
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice-daily rTMS (left prefrontal cortex, 10 Hz, 110% intensity, 1500 stimuli per session)
Study: 17176505
Drug: once-daily rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: once-daily rTMS
Study: 12197262
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline injections; n = 8)
Study: 7813493
Drug: Penicillin 3
Normalized name: clemizolpenicillin 300000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin 3 x 10(6) U/6 h plus ofloxacin 200 mg twice daily (group A)
Study: 7813493
Drug: Amoxicillin‐clavulanate 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanate 1 g/6 h plus erythromycin 1 g/8 h (group B)
Study: 409028
Drug: Progestogen-only oral
Normalized name: vaginal ring with progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestogen-only oral contraceptives
Study: 31838367
Drug: Benzodiazepine intake
Normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine intake factors (length of use and dose)
Study: 17522618
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (1 mg)
Study: 27467700
Drug: Focal psychodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal psychodynamic therapy (FPT)
Study: 27609525
Drug: Enhanced cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced cognitive-behavioural therapy (CBT-E)
Study: 27609525
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU-O)
Study: 25056510
Drug: Low-dose hydrocortisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydrocortisone therapy (steroid group)
Study: 11705307
Drug: Alitretinoin gel
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin gel 0.1%
Study: 9440643
Drug: Sorbitol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol (5 g)
Study: 10187002
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol
Study: 12515745
Drug: Effective nCPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective nCPAP treatment
Study: 10500312
Drug: Urokinase (UK)
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urokinase (UK) high-dose group (18,000 IU/kg, max 1.5 million IU)
Study: 24374502
Drug: ORV-116E vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORV-116E vaccine
Study: 24374502
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of ORV-116E vaccine
Study: 20542512
Drug: n‐3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 PUFA ethyl ester capsules
Study: 19025504
Drug: Early physiotherapy
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early physiotherapy intervention (education, reassurance, pain management, mobility training, interferential therapy, walking training, and walking aids)
Study: 14767409
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g/day for 1 week, then 3 g/day for 2 weeks)
Study: 15836828
Drug: Ulinastatin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin treatment (100 kU intravenously drip, once every 8 hours for 5 days)
Study: 29699021
Drug: Ulinastatin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin treatment
Study: 15836828
Drug: Ulinastatin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin treatment and Routine treatment
Study: 1974675
Drug: Tulobuterol 2
Normalized name: tulobuterol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol 2 mg tablets taken twice daily for 12 weeks
Study: 21743091
Drug: Receiving assistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving assistance with activities of daily living
Study: 22781526
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 µg × kg(‐1)× h(‐1)
Study: 22781526
Drug: Dexmedetomidine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.75 µg × kg(‐1)× h(‐1)
Study: 22781526
Drug: Dexmedetomidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1.0 µg × kg(‐1)× h(‐1)
Study: 22781526
Drug: Dexmedetomidine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (all doses) vs Control
Study: 10454704
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or no maintenance treatment
Study: 7561123
Drug: Candidate HIV‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidate HIV‐1 recombinant envelope subunit vaccines
Study: 2180792
Drug: cisapride 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisapride 0.15 mg/kg intravenously
Study: 2180792
Drug: cisapride 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisapride 0.2 mg/kg tid for 4 weeks
Study: 396057
Drug: BCG vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccines
Study: 28492860
Drug: Aflibercept, 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept, 2.0 mg
Study: 28492860
Drug: Bevacizumab, 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab, 1.25 mg
Study: 30676635
Drug: All anti-VEGF
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All anti-VEGF treatments
Study: 9766832
Drug: Lidocaine topical
Normalized name: lidocaine topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine topical anesthetic
Study: 26210387
Drug: SRP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP and PerioCol™CG (controlled-release device containing chlorhexidine)
Study: 27402391
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg/day
Study: 23638466
Drug: Glipizide titrated
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide titrated from 5 to 20 mg/day (mean dose 15 mg/day)
Study: 6775304
Drug: Topical nitroglycerin
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerin gel (15 to 30 mg)
Study: 6775304
Drug: Oral slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral slow-release nitroglycerin compound (Lénitral) 7.5 mg
Study: 12467334
Drug: Calcipotriene cream
Normalized name: Calcipotriene Cream
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcipotriene cream plus PUVA radiation
Study: 30876831
Drug: Pembrolizumab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks)
Study: 15292315
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg/d)
Study: 19088803
Drug: Enalaprilat (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (50 microg x min‐1 intracoronary infusion)
Study: 12105241
Drug: Persistent proteinuria
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Persistent proteinuria (UP) >1.0 g/24 h at diagnosis
Study: 10202242
Drug: Both Gd
Normalized name: Gd-HPDO3A
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both Gd doses after clinical relapses
Study: 121483
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without IPPB therapy)
Study: 28991063
Drug: Ropivacaine (0.625,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (0.625, 1.0, 1.5, 2.5, 4.0, or 6.25 mg)
Study: 28991063
Drug: Levobupivacaine (0.625,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (0.625, 1.0, 1.5, 2.5, 4.0, or 6.25 mg)
Study: 12823153
Drug: Omeprazole capsule
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole capsule 20 mg
Study: 12823153
Drug: Omeprazole MUPS
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole MUPS tablet 20 mg
Study: 8777954
Drug: Inhaled heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled heparin (1,000 U.kg‐1)
Study: 27824680
Drug: Azilsartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan (20 mg)
Study: 19918859
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) ointment
Study: 19367171
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (two-thirds of the total daily insulin dose required) subcutaneous administration with 5% dextrose solution infusion
Study: 19367171
Drug: Glucose-insulin-potassium (GIK)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium (GIK) infusion (125 ml/h)
Study: 16688803
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg bid)
Study: 11309553
Drug: Venlafaxine 37.5
Normalized name: venlafaxine 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 37.5 mg orally, 4 times with 12-hour intervals
Study: 2568202
Drug: bromazepam 1.5
Normalized name: bromazepam 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromazepam 1.5 mg bidaily (B)
Study: 2568202
Drug: labetalol 100
Normalized name: HCTZ 25/LABETALOL 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol 100 mg bidaily (L)
Study: 31124504
Drug: Conventional laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional laser treatment (control group)
Study: 25065959
Drug: Low-dose (LD)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose (LD) PLT prophylaxis
Study: 23062105
Drug: Sonic Irrigation
Normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonic Irrigation (SI) with 0.08 taper
Study: 21996202
Drug: mTOR inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: mTOR inhibitors with steroids
Study: 21996202
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (calcineurin inhibitor, mycophenolate mofetil or sodium plus steroids)
Study: 16508333
Drug: 10 IR
Normalized name: Yellow 10 Iron Oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 IR solution
Study: 16508333
Drug: 100 IR
Normalized name: Gentaved 100 Irrigation Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IR solution
Study: 16508333
Drug: 300 IR
Normalized name: ORALAIR 300 IR TAB,SL PKT 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IR solution
Study: 2105872
Drug: Triphasil (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasil (0.075 mg LNG, 0.040 mg EE2)
Study: 2105872
Drug: Trinordiol (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trinordiol (0.075 mg LNG, 0.040 mg EE2)
Study: 2105872
Drug: All formulations
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formulations (Triphasil, Trinordiol, Hydroalcoholic solution)
Study: 373956
Drug: Treatment center
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment center selection criteria
Study: 6833462
Drug: 2‐4 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐4 mg micronized estradiol given orally
Study: 6833462
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg estradiol orally
Study: 6833462
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg estradiol applied cutaneously
Study: 25040840
Drug: 0.2% plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% plain ropivacaine 0.75 ml·kg(‐1)
Study: 25040840
Drug: dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexmedetomidine 0.5 μg·kg(‐1) with 0.2% ropivacaine 0.75 ml·kg(‐1)
Study: 25040840
Drug: dexmedetomidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexmedetomidine 1.0 μg·kg(‐1) with 0.2% ropivacaine 0.75 ml·kg(‐1)
Study: 25040840
Drug: dexmedetomidine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexmedetomidine 1.5 μg·kg(‐1) with 0.2% ropivacaine 0.75 ml·kg(‐1)
Study: 20219398
Drug: Exposure in
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure in vivo treatment for back pain patients with low or moderate levels of catastrophizing
Study: 20219398
Drug: Exposure in
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure in vivo treatment for back pain patients with high levels of catastrophizing
Study: 17347859
Drug: Outox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outox (250 ml)
Study: 2135068
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 ml)
Study: 1282183
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg nicorandil
Study: 2137279
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg nicorandil
Study: 7433476
Drug: Oxymetazoline (0.025%)
Normalized name: Oxymethazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline (0.025%) ophthalmic solution, 2 drops 4 times daily
Study: 31651367
Drug: Psychodynamic case
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychodynamic case formulations made by experienced clinicians using simple experience-near language
Study: 29698983
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training (supervised thrice-weekly for 16 weeks)
Study: 20172547
Drug: Ketorolac and
Normalized name: Ketorolac and phenylephrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac and acetaminophen
Study: 17954514
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol plus promethazine
Study: 12829647
Drug: NN2211 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN2211 (7.5 micro g/kg)
Study: 9892294
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (day treatment and enhanced standard care)
Study: 31290996
Drug: Dasatinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (100 mg orally twice daily) plus Bevacizumab (10 mg/kg intravenously on day 1 of each 14-day cycle)
Study: 31290996
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Bevacizumab (10 mg/kg intravenously on day 1 of each 14-day cycle)
Study: 25274861
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine (IV adenosine)
Study: 17229423
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream applied for 40 minutes
Study: 15179345
Drug: Conventional anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anesthesia after shifting to insulin (I‐CA)
Study: 15179345
Drug: Conventional anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anesthesia plus isoflurane after shifting to insulin (I‐ISO)
Study: 15179345
Drug: Conventional anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anesthesia plus isoflurane (G‐ISO)
Study: 12507972
Drug: Vitamin B(12)
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B(12) (0.4 mg), folic acid (0.8 mg), and vitamin B(6) (40 mg)
Study: 9637646
Drug: Epidural saline-intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline-intravenous fentanyl (20 microg/h)
Study: 9637646
Drug: Epidural saline-intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline-intravenous saline (control)
Study: 9637646
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (20 microg/h)
Study: 3189722
Drug: Topical beclomethasone
Normalized name: beclomethasone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical beclomethasone dipropionate 100 micrograms in each nostril twice daily for 4 weeks